BioSpace News Archive

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters’ option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer, Mark Foley, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, Chief Executive Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference.

vTv Therapeutics Inc. announced it has entered into a common stock purchase agreement for up to $47 million with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.

Stealth BioTherapeutics Corp (Nasdaq: MITO) (“Stealth” or the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the closing of its previously announced registered direct offering of 2,844,446 of its American Depositary Shares (“ADSs”),

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and full year Fiscal 2020 ended August 31, 2020 on Monday November 30th, 2020 before market open.

Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO, announced the completion of the previously announced offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029.

Oncopeptides AB, a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases, announces that the company has finalized the program for the upcoming virtual capital markets day for investors, analysts and journalists on November 30th, 2020.

Braid Health has secured FDA clearance for its AI-powered diagnostic collaboration software, improving diagnostic access and reducing costs for large healthcare systems, urgent care clinics, and retail clinics.

Annual program honors individuals for their outstanding efforts in making a difference for patients living with myeloproliferative neoplasms (MPNs)